Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

During a two-day session in Ahmedabad, Congress leaders, including Mallikarjun Kharge and Rahul Gandhi, intensified their criticism of the BJP and RSS, particularly regarding religious freedom and ...